期刊文献+

甲型H1N1流感病毒株的分离鉴定以及PR8株的相关基因对重组病毒增殖能力的影响

Isolation of an HIN1 influenza A virus and identification of genes influencing on the replication of reassortant virus with PR8 backbone
下载PDF
导出
摘要 为分离流感病毒,本研究将疑似甲型流感患者的咽喉拭子接种SPF鸡胚尿囊腔,经检测收获的鸡胚尿囊液具有血凝活性。采用流感病毒通用引物进行PCR扩增出8个基因节段,经测序与GenBank中登录的序列比对后确定该病毒株为2009年爆发的甲型H1N1流感病毒,并命名为A/Harbin/LM/2009(H1N1),简称LM株。由于LM分离株在鸡胚中增殖能力比较弱,为提高其在鸡胚中的增殖能力,我们利用反向遗传技术将LM株的HA和NA基因与高增殖特性的人流感病毒细胞高产株PR8的另外6个节段进行"6+2"重配,获得拯救病毒,但该重配病毒血凝价并未显著提高。为进一步鉴定影响病毒增殖能力的基因,本研究将LM株所有节段以"7+1"的方式逐一与PR8的7个片段搭配构成完整的流感病毒基因组,分别得到8个重配病毒。结果显示分离株的PB1、PA、HA基因显著降低了重配病毒在鸡胚细胞中的增殖能力。 In this study, a virus was isolated from an adult throat swab in Harbin and identified as an H1N1 influenza virus by hemagglutination test and gene sequencing, designated A/Harbin/LM/2009 (H1N1). To improve the replication capacity of the isolate in embryoed eggs, we utilized reverse genetics technique to construct "6+2" reassortant virus, which included HA and NA segments of the isolate and the remaining segments of high-yield influenza virus PR8, as a result the HA titer of the reassortment virus was not significantly improved. To further identify which segment was critical to replication capacity of reassortant virus. A total of 8 reassortment viruses were constructed with 7 segments from PR8 and one segment from the isolate as a "7+1" strategy. The results showed that PB1, PA and HA segments of the isolate dramatically reduced the replication capacity of reassotant virus with PR8 backbone.
出处 《中国预防兽医学报》 CAS CSCD 北大核心 2011年第7期517-520,共4页 Chinese Journal of Preventive Veterinary Medicine
基金 黑龙江省自然科学基金(ZJN0702-02) 现代农业水禽技术体系(CARS-43)
关键词 甲型H1N1流感病毒 反向遗传 重配 增殖能力 H1N1 influenza A virus reverse genetics reassortment replication capacity
  • 相关文献

参考文献6

二级参考文献47

  • 1Hoffmann E, Stech J, Guan Y, et al. Universal primer set for the fulllength amplification of all influenza A viruses. Arch Virol, 2001, 146 ( 12): 2275-2289.
  • 2Barrett PN, Mundt W, Kistner O, et al, Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines, 2009, 8 (5): 607-618.
  • 3Mendelman PM, Cordova J, Cho I. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, coldadapted(CAIV2T) in healthy children and healthy adults. Vaccine, 2001, 19(17-19): 2221-2226.
  • 4Seo SH, Hoffmann E, Webster RG. Lethal H5N1 influenza virus esescape host anti-viral cytokine responses. Nat Med, 2002, 8(9): 950-954.
  • 5Audsley JM, Tannock GA. Cell-based influenza vaccines: progress to date. Drugs, 2008, 68 ( 11 ): 1483-1491.
  • 6Kistner O, Barrett PN, Mundt M, et al. Development of a Veto cellderived influenza whole virus vaccine. Dev Biol Stand, 1999, 98: 101-110.
  • 7Ha SH, Kim HA, Kim YH, et al. A multiplex RT-PCR medhod for screening of reassortant live influenza vaccine virus strains. J Virol Mtd, 2006,134 (1-2): 154-163.
  • 8Webby R J,Perez D R,Coleman J S,et al.Responsiveness to a pandemic alert:Use of reverse genetics for rapid development of influenza vaccines[J].The Lancet,2004,363:1 099-1 103.
  • 9WHO guidance on development of influenza vaccine reference viruses by reverse genetics:(WHO/CDS/CSR/GIP/2005.6)[EB/OL].Geneva:World Health Organization,2005[2009-05-12].http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_6/en/index.html.
  • 10Bresson J L,Perronne C,Launay O,et al.Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine:Phase I randomized trial[J].The Lancet,2006,367:1 657-1 664.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部